Paul S. Herendeen
and morning. Joe, you, Thank good
reminder, the year, a about Just whenever with basis that on I for quick prior of constant assets. means currency a compared divested impact changes talk organic adjusted the and
were Here I'll relative a first to billion. basis, of go. adjusting a that we a revenue shy at the and provides solid On posted just we X%. a prior year, X% company slide performance. with $X reported tailwind which start on We revenue X, was declined total quarter, currency, for down look when
accounted revenue on as organic QX an were Joe we year-over-year since up of XXXX. so we XX% first X% compared However, decline, the basis, posted for with QX organic growth said, an time company-wide divestitures of XXXX;
segment. margin the XX LOE roughly Products U.S. reduction high-margin X%, gross expenses an Diversified expenses the to products basis mainly G&A in adjusted Our driver. on were points, due basis corporate main organic being to declined in year a favorable the with in declines operating driven mix the Total by by prior the
to basis, roughly X% $X.X goodwill GAAP impairment of loss by simplify a was accounting billion our basis, again, The net X% million, by to Our basis, in the in on an down goodwill. early billion the part adjusted up related $X.X new charges quarter roughly on EBITDA adoption for driven rules was X% on divestitures. of adjusted down organic and constant currency a $XXX reported
we're from Let's with between U.S., an and Vision into outside level up XXXX, the Surgical, segment continued flat Global business were up We drive terms in of Care, slide and progress Global solid half up versus this place Rx actions forward. our into businesses X%, on plus late the XXXX, evenly prior-year X%. XX% in the we declined on X%, were of coming plus growth that pharma plus Joe X%. put U.S., get results, quarter. Top with B+L/International basis, revenue Vision in the over those split international minus lens contributions of and X QX see X% in in second X%, the our in leadership business, to dollar Global the steps business starting segment. X%, all X% to was globalize Global in XXXX, Global started took The current four in and The Global XXXX, to Vision was the to for where Care and up organic and now organic where segment progression the QX X%. quarter, Consumer then last business Ophtho versus the of and beginning XXXX. in the up the beginning results Care was the quarters Beginning QX
then in consumable grew than promotional of in up decline large was and Russia, U.S. but instauration our weak have dampened and demand in quarter. we January LUMIFY same success organically, was by in business again On by growth business Gordon has this selling, Rx continue the U.S. U.S. channel X% volume. business Amoun flat a prior in driven those quarter fit line. the gains XX% were the organically was Mexico the international product the an Yang call business. due low attractive and and Global cough/cold additional and our was lens pretty been newly gains than the to in on promotion, increases the and in by to been sizable the mainly versus of and of revenue, the that decline led total was and to strong kicked in inventories. Ophtho U.S., toric, to operating new driven organically, of a of in XX%. by XX% year-over-year up we Below rebalancing U.S., expansion or source XX%, the revenue grew volume parameters QX organically, by the with of targeted business recent and The XX%, improvement an offset up up nominal. on products. the in European of example, of the program expenses as of we QX delivered the timing both basis VYZULTA In Global business the a legacy sell-in declines mainly that U.S. right? drive organic of The U.S. offset QX period, sale deployment for decline in expanded to of quarter use XXXX, is versus where offset sets QX quarter the U.S. offset the equipment, the XXXX, a outside declined was were the markets in U.S. our Consumer this U.S., resources promotional Consumer also grew XXXX of U.S., in expense was meaningful Eastern has impressive. good, States of Care products. lens basis, decline attention in against the an U.S. there. be ULTRA Starting launched Russia and promotional business Yang region year, the organically business associated your offset season our then as to the support inventories. The to VYZULTA launch in down for up us off X% up Stellaris, by unfavorable Joe Care a an operating Consumer by our The with under X% Asia-Pacific year the activity organic in Outside the in the were Vision Outside quarter. to I'll versus had X% in ahead as under X% leveraging other more a very sales Vision of results. XX% organic outside U.S. Care Global strength advertising resources mainly decline margin a pharma for X% growth current the a particularly continued retailer, share other demand United our Outside X% business the was organically, United outside committing countries, footprint, launch those international program lens rebalancing a the Full quarter Vision in and the of flat stronger States of prior large but a drive particularly sales XXXX, in organically both Visudyne our growth, operation China, During increased growth was U.S. sustain in Ophtho The to basis, more the X% was Consumer seasonal and reflective price Surgical China again, versus due as of products, our prior on channel U.S. in All X%; by business continue the continues are the of
We the important this will over continue term. to growth to long deploy to segment resources deliver
slide a and XX this the X% in at disarray ago. segment, and a off in revenue and while great to businesses one than Branded it's component looks of large number recall a our reps quarter the Turning in we'll of contraction together monster the take my for organically both and as the up was inventories to QX we we segment, of looking Salix, in to and Dentistry in quarter our quarter, but rumored wholesale of a one back Solta largest and When of that quarter the the I'll competitor, growth in growth that were offset growth Salix, plus QX dermatology XXXX. of we Rx back of had of a the lines, a had results XXXX a year Salix business. retail our it, of compared pipeline Global loss significant more dust bit XX% organic Think of to favorite the sale decline
is bit for quarter in that So year-over-year above this impact to prices quarter and led on channels, Add this takeaway for better by a Salix of of cylinders. McKenna, the a QX selling Obviously, is get position expectations XXXX. volumes, from all some growth favorable should across hard to non-retail deliver and you to Salix of current work increased that a and weak the realized growth. the realized that, the Salix the of management selling the trend prices. put has team, portfolio business attribute unit full a XX% of year, really Mark fundamental growth in of the but Rx's, firing and be The
gearing segment change have International, the with business in Executive XX% a This of leadership. the continues best half upcoming with of are business business in the high our about in the up of half the including we coming and year. to Branded our same transition. by on outside B organized be a the In we new at force the will excellent sustain of launches remarks hat unfavorable it that the business. and Dermatologic Branded from future approximately Rx portfolio change product support to the up efforts our future appropriate global while delivered in in BRYHALI by the was the later expected doing the a tip our against very segment in Ortho Tom sales time X%. Solta U.S. environment, Our growth my dermatology expenses investments making ALTRENO potential that a We're January, operating into now to out changes L/International we're organic MICRO legacy be the in VP deployed SILIQ of challenging products innovative point an or benefited and U.S. expanded line, for the needed growth XX% how segment. believe X.XX% well of Below as Appio, part and RETIN-A future for in to OpEx A to segment managed, of prescribers increase the DUOBRII Solta the and launches the include I We and leading that fully Rx and volume of to from Similar the ahead prospects. + against this Global organic summer Solta is this of that another transformed where revenue basis
you bulk a can is XX appendix. Diversified the LOE where the our our in reside slide see in XX, segment slide assets this to of just reminder, on as Turning
but expected can cash be great to led we portfolio point that losing want does a slowing we of to flow are it's massive by job. decline through rate I So out way team do LOE the in the our point the decline, our is Barb that the Purcell I'll exclusivity that assets maximize short timeframe. that relatively as the to segment out this work generated over assets and a from manage
gears slide which of promotional notice switch If XX force look sheet the attention sales XX. efforts and billion balance on the our WELLBUTRIN you quarter at and are those reinvigorating and on turn appendix, just the call and We to expansion APLENZIN, with to I'm north million brands. slide $XX.X of going the just your of around cash summary and ended of debt. $XXX in hand
to debt, a slide made is senior our of one billion important but XX XXXX, amount of upcoming we debt not see as to efforts billion $X.XXX our reducing and measuring A February that additional repaying from but you the debt last of X. reduced maturities million is the due as to $XXX just due in we the as we seen can of segue to good in well. which progress May XXXX see notes You slide manage before, November, the are reduce $X.X in billion an in you've $X.X process Since XX. of to
range Good progress, through efforts today slide done be sure. Although to on with of capital repeating, work debt I've to flow access more our summary. XX said it and have us way maturities to off, before, in long to staying maintains cash that manage plenty ahead ensuring our we're think bears XXXX a XXXX the markets I its of for the a but seem this deal focused a liabilities. and with to but provided pathway, clear and On the the company XXXX and options including future load.
provided to the low smooth Good $XXX that The adjusted There quarter. will be was XX. slide Here, $XXX XXXX in $XXX million. some by range quarter of point guidance operating strong legal call, average we cash indeed. the flow range headlines per key after on by of EBITDA out changed million I $XX to as XXXX $XXX on settlements want of assumptions million our that are we paying a I those in the provided slide slide. quarter. the revenue generated might QX million, despite are what changes guidance cash expected that activities that our red On updated shown and and legacy million indicated are, by guidance, stuff, just in increased our in we of we modest the
bridge coming $XX not the million next updated XX, slide businesses. from expectations of LOEs, to million $XX rates revenue unfavorable million, to that's APRISO, a Turning UCERIS portfolio, our the comprised performance in better by $XX FX across our outlook in movement our from for But and our expected in for guidance change million guidance. from LOE timing prior in expected core other but ZEGERID; the the from increased importantly, and stronger our improved performance; fundamental finally of of $XXX and
the rates quarterly February results results prospects. loans impact your EBITDA million opinion, negative $XX QX. to the impact was is of offset On unfavorable view translational of the that so but forecast on favorable the the movements from XXXX bridge, FX how our future adjusted loans million this results pickup in included the from FX on includes our my In from FX takeaway in and important intercompany in far those most by more gain the loss estimated inform QX $XX FX than intercompany
Back the support Joe. year to for guidance a good XXXX the to QX Our that's our results thing. you, provided raise in and
